It’s one of those things that feels obvious when you’re the one living it. Manage a chronic disease well, and you need less emergency care down the road. Obesity is … Continue readingThe “No Proof” GLP-1 Insurance Excuse Just Got Weaker
Some research findings feel obvious the moment you read the headline. Combining a GLP-1 with exercise works better than either one alone? Of course it does. But “obvious” and “actually … Continue readingWhat the Data Says About Stacking GLP-1s and Exercise
123%. That’s how much higher the risk of death was for people over 50 who had both abdominal obesity and vitamin D deficiency, compared to people with neither. A new … Continue readingThe Feedback Loop That Doubles Your Death Risk
For years, the tirzepatide-versus-semaglutide debate has been fought with one hand tied behind everyone’s back. Both drugs had impressive trial results, but no study had ever put them head-to-head in … Continue readingTirzepatide vs. Semaglutide: We Finally Have Head-to-Head GLP-1 Data
Semaglutide is one of the most effective obesity medications ever developed, and it’s still teaching scientists new things about how the brain works. A recent Yale study just uncovered a … Continue readingThe Hunger Cells That Switched Sides
Starbucks just told its employees that GLP-1s are off the list. It’s part of a disturbing and growing trend of employers dropping GLP coverage. Drugs like Wegovy, Zepbound, and Saxenda … Continue readingWhen Your Treatment Becomes a Line Item
Twenty-seven percentage points. That’s how much more likely an unemployed woman was to land a job within a year and a half of starting a GLP-1, compared to a woman … Continue readingLosing Weight Didn’t Make Them Better Employees… It Made Them Hireable